Bausch Health Companies Inc. (TSE:BHC) Director John Paulson Buys 514,549 Shares

Bausch Health Companies Inc. (TSE:BHC) Director John Paulson purchased 514,549 shares of the firm’s stock in a transaction that occurred on Wednesday, June 11th. The stock was bought at an average price of C$7.13 per share, for a total transaction of C$3,666,881.99.

John Paulson also recently made the following trade(s):

• On Friday, June 13th, John Paulson purchased 1,782,030 shares of Bausch Health Companies stock. The stock was bought at an average price of C$8.14 per share, for a total transaction of C$14,501,803.73.
• On Thursday, June 12th, John Paulson purchased 502,688 shares of Bausch Health Companies stock. The stock was bought at an average price of C$7.44 per share, for a total transaction of C$3,739,596.57.
• On Tuesday, June 10th, John Paulson purchased 754,134 shares of Bausch Health Companies stock. The stock was bought at an average price of C$6.87 per share, for a total transaction of C$5,179,392.31.

Bausch Health Companies Stock Down 2.6%

Shares of TSE BHC opened at C$7.80 on Wednesday. The company has a debt-to-equity ratio of -1,831.94, a quick ratio of 0.58 and a current ratio of 1.19. Bausch Health Companies Inc. has a 52 week low of C$5.45 and a 52 week high of C$13.74. The stock has a market capitalization of C$2.03 billion, a P/E ratio of -11.41, a PEG ratio of 0.21 and a beta of 0.77. The stock’s fifty day moving average is C$6.75 and its 200 day moving average is C$9.05.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.